Enzyme-Replacement Therapy in Mucopolysaccharidosis I: Influence Statistics

Expert Impact

Concepts for which they have has direct influence: Patients mucopolysaccharidosis , 52 weeks , Age patients , Iduronidase patients , Alpha iduronidase , 52 weeks patients , 26 weeks .

Key People For Patients Mucopolysaccharidosis

Top KOLs in the world
#1
Michael H Beck
fabry disease allergic contact dermatitis enzyme replacement therapy
#2
James Edmond Wraith
enzyme replacement therapy mucopolysaccharidosis type hurler syndrome
#3
Joseph Muenzer
hunter syndrome enzyme replacement therapy mucopolysaccharidosis type
#4
Roberto Giugliani
fabry disease mucopolysaccharidosis type enzyme replacement therapy
#5
J John Hopwood
mucopolysaccharidosis type lysosomal storage mps iiia
#6
Paul R Harmatz
hunter syndrome iron overload elosulfase alfa
Similar searches    patients mucopolysaccharidosis

Enzyme-Replacement Therapy in Mucopolysaccharidosis I

Abstract

. BACKGROUND: Mucopolysaccharidosis I is a lysosomal storage disease caused by a deficiency of the enzyme alpha-L-iduronidase. We evaluated the effect of enzyme-replacement therapy with recombinant human alpha-L-iduronidase in patients with this disorder. METHODS: We treated 10 patients with mucopolysaccharidosis I (age, 5 to 22 years) with recombinant human alpha-L-iduronidase at a dose of 125,000 U per kilogram of body weight given intravenously once weekly for 52 weeks. The patients were evaluated at base line and at 6, 12, 26, and 52 weeks by detailed clinical examinations, magnetic resonance imaging of the abdomen and brain, echocardiography, range-of-motion measurements, polysomnography, clinical laboratory evaluations, measurements of leukocyte alpha-L-iduronidase activity, and urinary glycosaminoglycan excretion. RESULTS: Hepatosplenomegaly decreased significantly in all patients, and the size of the liver was normal for body weight and age in eight patients by 26 weeks. The rate of growth in height and weight increased by a mean of 85 and 131 percent, respectively, in the six prepubertal patients. The mean maximal range of motion of shoulder flexion and elbow extension increased significantly. The number of episodes of apnea and hypopnea during sleep decreased 61 percent. New York Heart Association functional class improved by one or two classes in all patients. Urinary glycosaminoglycan excretion decreased after 3 to 4 weeks of treatment; the mean reduction was 63 percent of base-line values. Five patients had transient urticaria during infusions. Serum antibodies to alpha-L-iduronidase were detected in four patients. CONCLUSIONS: In patients with mucopolysaccharidosis I, treatment with recombinant human alpha-L-iduronidase reduces lysosomal storage in the liver and ameliorates some clinical manifestations of the disease.